Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, China.
Department of Ophthalmology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, China.
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211010143. doi: 10.1177/15330338211010143.
This present study aims to investigate the potential prognostic values of dynactin genes ( for predicting the overall survival (OS) in low-grade glioma (LGG) patients.
The mRNA expression data were downloaded from The Cancer Genome Atlas database containing 518 patients with LGG. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses for genes were performed by using Database for Annotation, Visualization, and Integrated Discovery platform, and their enrichment results were verified by using the Biological Networks Gene Ontology tool. Next, the correlations between genes and LGG were identified by Pearson correlation coefficient analysis. The OS was estimated by Kaplan-Meier survival analysis. The cBio Cancer Genomics Portal was used to analyze the mutations of genes and their effects on the prognosis of LGG. The correlation between the abundance of immune infiltration and tumor purity of genes were predicted by The Tumor Immune Estimation Resource.
Our research showed that the mRNA expression of in tumor tissues was much higher ( < 0.01) than that in normal tissues. Meanwhile, there was a certain correlation between the genes. Survival analysis showed that the high expression of , , , , and their co-expression were significantly correlated with favorable OS in LGG patients ( < 0.05). In , a high mutation rate was observed. Further research showed that the genetic alteration in genes was related to a poor OS and progression-free survival of LGG patients. The expression of genes had a certain correlation with immune infiltrating cells.
Our study showed that the high expressions of , , , and were associated with a favorable OS of LGG patients, indicating that these genes are potential biomarkers for evaluating the prognosis of LGG patients.
本研究旨在探讨动力蛋白激活因子（dynactin）基因在预测低级别胶质瘤（LGG）患者总生存期（OS）中的潜在预后价值。
从包含 518 例 LGG 患者的癌症基因组图谱（TCGA）数据库中下载 mRNA 表达数据。使用数据库注释、可视化和综合发现平台（DAVID）对基因进行基因本体论（GO）和京都基因与基因组百科全书（KEGG）分析，并使用生物网络基因本体论工具验证其富集结果。接下来，通过 Pearson 相关系数分析鉴定基因与 LGG 之间的相关性。采用 Kaplan-Meier 生存分析估计 OS。使用 cBio 癌症基因组学门户分析基因的突变及其对 LGG 预后的影响。通过肿瘤免疫评估资源预测基因免疫浸润丰度与肿瘤纯度的相关性。
我们的研究表明，肿瘤组织中基因的 mRNA 表达水平明显高于正常组织（<0.01）。同时，基因之间存在一定的相关性。生存分析显示，基因的高表达与 LGG 患者良好的 OS 显著相关（<0.05）。在基因中观察到较高的突变率。进一步研究表明，基因的遗传改变与 LGG 患者的不良 OS 和无进展生存期有关。基因的表达与免疫浸润细胞有一定的相关性。
本研究表明，基因的高表达与 LGG 患者良好的 OS 相关，表明这些基因是评估 LGG 患者预后的潜在生物标志物。
